Clinical trials: Head and Neck Squamous Cell Carcinomas
Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.
- Trial name
- RAD RAPTORS (NCT07044635)
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Utah
Head & Neck Cancer
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
This is an open-label, single arm, multicenter phase 2 study. The study is to evaluate the activity of a combination therapy with nal-IRI (PEP02, MM-398, Onivyde®) plus 5-FU and leucovorin in patients with squamous cell carcinoma…
- Trial name
- NCT03712397
- Testing
- nanoliposomal irinotecan
- Where
- 4 sites in Taiwan
- Volunteers
- 59 people
- Sponsor
- National Health Research Institutes, Taiwan
Papillary Thyroid Carcinoma
Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?
study assigned into three groups, Group I was the control group operated by total thyroidectomy and retrospectively followed, where the other two groups Operated by Total thyroidectomy and central neck dissection.
- Trial name
- NCT04336696
- Testing
- Total thyroidectomy and central neck dissection
- Where
- Egypt
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Bassem Mohamed Sieda
Nasopharyngeal Carcinoma
Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma
Objectives: Primary objective To determine the efficacy of Foscan-PDT compared with Brachytherapy for recurrent or persistent NPC, as determined by macroscopic clinical examination, CT scan and biopsy.
- Trial name
- FOSCAN (NCT01086488)
- Testing
- FOSCAN
- Where
- 5 sites in Malaysia
- Volunteers
- 66 people
- Sponsor
- Ministry of Health, Malaysia
Head and Neck Neoplasms
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
This proof-of-concept study aims to assess the clinical and biological effects of Atezolizumab combined with Bevacizumab in advanced previously treated squamous-cell carcinoma of the head and neck (HNSCC).
- Trial name
- ATHENA (NCT03818061)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 7 sites in France
- Volunteers
- 33 people
- Sponsor
- Centre Leon Berard
Esophageal Cancer, Chemoradiotherapy
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
This trial is a prospective, randomized, controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of sintilimab as consolidation therapy in elderly patients with esophageal cancer who did not progress…
- Conditions
- Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
- Trial name
- NCT06413342
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Cancer
Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer
Correlation between serum squamous cell carcinoma antigen level and tumor volume in Head and Neck Cancer is to determine a correlation between level of serum squamous cell carcinoma antigen and tumor volume in Head and Neck Caner…
- Trial name
- NCT02879968
- Testing
- Non-interventional study
- Where
- Thailand
- Volunteers
- 52 people
- Sponsor
- Prince of Songkla University
Head and Neck Squamous Cell Carcinoma
A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to confirm the safety and efficacy of Apatinib in Combination With Radiotherapy / Chemotherapy for Second-line and Above Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT03424291
- Testing
- Apatinib plus chemoradiation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
This is an open-label, prospective, randomized, Phase III, international multicenter clinical study to compare radiotherapy plus nimotuzumab versus radiotherapy alone in platinum-ineligible patients with locoregionally advanced…
- Trial name
- NCT07333274
- Testing
- Nimotuzumab, intensity-modulated technique（IMRT）
- Where
- China
- Volunteers
- 335 people
- Sponsor
- Shandong Cancer Hospital and Institute
Head and Neck Cancer, Head and Neck Neoplasms
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Background: Some people who get head and neck cancer will need surgery to treat their cancer. Research suggests that immunotherapy drugs may help fight head and neck cancer if given before surgery.
- Trial name
- NCT04247282
- Testing
- M7824, N803, TriAd vaccine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma
Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
The goal of this multicenter retrospective cohort study is to evaluate the impact of different pathological regression types on survival and recurrence patterns, with a particular focus on ypT0N+ patients in patients with…
- Trial name
- NCT06241079
- Testing
- non-intervention
- Volunteers
- 582 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00445861
- Testing
- cetuximab + docetaxel + cisplatin, Treatment level 1, Treatment level 2
- Where
- 2 sites in Switzerland
- Volunteers
- 27 people
- Sponsor
- Swiss Cancer Institute
Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy
This phase I trial studies the side effects and best dose of entolimod in treating patients with stage III-IV or recurrent head and neck cancer.
- Conditions
- Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01728480
- Testing
- entolimod, intensity-modulated radiation therapy, cisplatin
- Sponsor
- Roswell Park Cancer Institute
Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
The goal of this clinical trial is to learn about the efficacy and safety of pablizumab combined with neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Immunotherapy
- Trial name
- NCT06125223
- Volunteers
- 45 people
- Sponsor
- Xijing Hospital
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it…
- Trial name
- NCT03666273
- Testing
- Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bayer
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral injection in subjects with cutaneous…
- Trial name
- NCT04502888
- Testing
- Drug: SL-172154
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Shattuck Labs, Inc.
Carcinoma, Hepatocellular, Gastric Adenocarcinoma
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in…
- Conditions
- Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer
- Trial name
- VALUE-CHECK (NCT06422403)
- Testing
- Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C
- Where
- Singapore
- Volunteers
- 360 people
- Sponsor
- National University Hospital, Singapore
Cutaneous Squamous Cell Carcinoma
Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck
The goal of this clinical trial is to learn if the combination of the drug cemiplimab along with a short course of radiation therapy called Quad Shot can be successfully given in several rounds to elderly or frail patients with…
- Trial name
- NCT07869823
- Testing
- Cemiplimab, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Squamous Cell Carcinoma
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Radical resection is thought to be the mainstay of esophageal cancer treatment. Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer…
- Trial name
- NCT04644250
- Testing
- Toripalimab, Paclitaxel liposome/Carboplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Wei Ren
Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck.
- Conditions
- Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT00084682
- Testing
- romidepsin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.